A Phase 2, Observer-Blinded, Randomized, Multicenter Study in Healthy Adults to Evaluate Safety and Tolerability and to Compare Immunogenicity of a Single Dose of Either an Investigational Trivalent Inactivated Influenza Vaccine Produced in Mammalian Cell Culture or a US-licensed Trivalent Inactivated Influenza Vaccine (Fluvirin®) Produced in Embryonated Hen Eggs

Trial Profile

A Phase 2, Observer-Blinded, Randomized, Multicenter Study in Healthy Adults to Evaluate Safety and Tolerability and to Compare Immunogenicity of a Single Dose of Either an Investigational Trivalent Inactivated Influenza Vaccine Produced in Mammalian Cell Culture or a US-licensed Trivalent Inactivated Influenza Vaccine (Fluvirin®) Produced in Embryonated Hen Eggs

Completed
Phase of Trial: Phase II

Latest Information Update: 03 Apr 2017

At a glance

  • Drugs Influenza virus vaccine (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Chiron Corporation; Novartis
  • Most Recent Events

    • 10 Jun 2011 Actual end date (May 2006) added as reported by ClinicalTrials.gov.
    • 10 Jun 2011 Actual initiation date (Oct 2005) added as reported by ClinicalTrials.gov.
    • 15 Sep 2009 Primary endpoint 'Geometric mean antibody titre' has been met; results published in Journal of Infectious Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top